Diagnostic performance of bone scintigraphy and 11C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer

被引:15
|
作者
Garcia, J. R. [1 ]
Moreno, C. [1 ]
Valls, E. [1 ]
Cozar, P. [1 ]
Bassa, P. [1 ]
Soler, M. [1 ]
Alvarez-Moro, F. J. [1 ]
Moragas, M. [1 ]
Riera, E. [1 ]
机构
[1] Unidad PET CETIR ERESA, Barcelona, Spain
关键词
Bone scintigraphy; C-11-Choline PET/CT; Bone metastases; Biochemical recurrence; Prostate cancer; POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; F-18-FLUORIDE PET; F-18-FDG PET/CT; DISEASE; SPECT; ONCOLOGY; RELAPSE; CT;
D O I
10.1016/j.remn.2014.08.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: To compare bone scan (BS) with C-11-Choline PET/CT for the detection of bone metastases in patients with biochemical recurrence of prostate cancer (PC). Material and Methods: A total of 169 patients with biochemical recurrence of PC(PSA:2.4-58 ng/ml) who were referred for both exams (0-15 days-in-between) were included. Lesion-detection-rate per patients and lesions were analyzed for both BS and C-11-Choline PET/CT. Metastasis diagnosis was reached by: biopsy, CT/F-18-Fluoride PET/MRI confirmation, or evidence of progression in subsequent imaging procedures. Results: A total of 91 lesions were found to be active in BS and/or C-11-choline PET/CT (40 patients), with 78 of which were metastatic. BS detected 38 blastic, 2 lytic and 10 non-CT-evident lesions. C-11-Choline PET/CT detected 41 blastic, 4 lytic and 29 non-CT-evident lesions. BS and C-11-Choline PET/CT sensitivities were 65.4% and 96.1%; specificities ere 38.5 and 92.3% (chi(2) 8.27, p < 0.04). Both imaging techniques were negative in 118 patients. Tracer avid lesions were found in 51 patients: with 30/51 being BS and C-11-Choline PET/CT concordant; in 21/51 patients had discordant lesions (kappa 0.712, p = 0.00). Lesions were absolutely discordant in 10/19 patients,: 5 FN BS, 2 FP BS (degenerative changes: dysplasia), 1 FN C-11-Choline PET/CT (blastic), 1 FP C-11-Choline PET/CT (degenerative), 1 out of field-of-view lesion with C-11-Choline PET/CT (tibia alone). C-11-Choline PET/CT showed extraosseous involvement in 26/51 patients with bone metastases: 9 local recurrences, 5 infra-diaphragmatic-lymph-nodes, 2 supra-diaphragmatic, 5 local and infra-diaphragmatic, 4 infra- and supra-diaphragmatic, 1 supra-diaphragmatic and lung metastases. Conclusion: C-11-Choline PET/CT yielded better sensitivity and specificity than BS for the detection of bone involvement in patients with biochemical recurrence of PC and allowed extraosseous restaging, with an impact in the clinical management of these patients. (C) 2014 Elsevier Espana, S.L.U. and SEMNIM. All rights reserved.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 50 条
  • [31] Influence of 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer
    Souvatzoglou, Michael
    Krause, Bernd J.
    Puerschel, Anja
    Thamm, Reinhard
    Schuster, Tibor
    Buck, Andreas K.
    Zimmermann, Frank
    Molls, Michael
    Schwaiger, Markus
    Geinitz, Hans
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 (02) : 193 - 200
  • [32] Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
    Seitz, M
    Gratzke, C
    Schlenker, B
    Reich, O
    Stief, CG
    Scher, B
    JOURNAL OF UROLOGY, 2006, 175 (04): : 483 - 484
  • [33] Imaging prostate cancer with 11C-choline PET/CT
    Reske, Sven N.
    Blumstein, Norbert M.
    Neumaier, Bernd
    Gottfried, Hans-Werner
    Finsterbusch, Frank
    Kocot, Darius
    Moeller, Peter
    Glatting, Gerhard
    Perner, Sven
    JOURNAL OF NUCLEAR MEDICINE, 2006, 47 (08) : 1249 - 1254
  • [34] 11C-Choline PET/CT in Recurrent Prostate Cancer
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (01) : 24N - 24N
  • [35] The role of bone scintigraphy in detection of bone metastases of prostate cancer in patients with biochemical recurrence after radical prostatectomy
    Demeshko, P. D.
    Sukonko, O. G.
    Krasny, S. A.
    ONKOUROLOGIYA, 2012, 8 (04): : 70 - 76
  • [36] Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
    Bernhard Scher
    Michael Seitz
    Wolfram Albinger
    Reinhold Tiling
    Michael Scherr
    Hans-Christoph Becker
    Michael Souvatzogluou
    Franz-Josef Gildehaus
    Hans-Jürgen Wester
    Stefan Dresel
    European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34 : 45 - 53
  • [37] Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
    Scher, Bernhard
    Seitz, Michael
    Albinger, Wolfram
    Tiling, Reinhold
    Scherr, Michael
    Becker, Hans-Christoph
    Souvatzogluou, Michael
    Gildehaus, Franz-Josef
    Wester, Hans-Juergen
    Dresel, Stefan
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (01) : 45 - 53
  • [38] 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT
    Francesco Ceci
    Paolo Castellucci
    Tiziano Graziani
    Riccardo Schiavina
    Eugenio Brunocilla
    Renzo Mazzarotto
    Maria Ntreta
    Filippo Lodi
    Giuseppe Martorana
    Stefano Fanti
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 878 - 886
  • [39] 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT
    Ceci, Francesco
    Castellucci, Paolo
    Graziani, Tiziano
    Schiavina, Riccardo
    Brunocilla, Eugenio
    Mazzarotto, Renzo
    Ntreta, Maria
    Lodi, Filippo
    Martorana, Giuseppe
    Fanti, Stefano
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) : 878 - 886
  • [40] Role of 11C-CHOLINE PET/CT for Early Detection of Localized Prostate Cancer
    Farsad, M.
    Nanni, C.
    Castellucci, P.
    Franchi, R.
    Ambrosini, V.
    Allegri, V.
    Palucci, A.
    Schiavina, R.
    Martorana, G.
    Corti, B.
    Grigioni, W.
    Boschi, S.
    Lodi, F.
    Levorato, M.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S115 - S115